Contemporary management of hepatocellular carcinoma.
Palmer
Daniel
D
Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston. d.palmer@bham.ac.uk
D001557:Benzenesulfonates / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery / Q000628:therapy*; D017115:Catheter Ablation; D016461:Chemoembolization, Therapeutic; D006498:Hepatectomy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007459:Iodized Oil; D008113:Liver Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery / Q000628:therapy*; D016031:Liver Transplantation; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011379:Prognosis; D011725:Pyridines / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects; D012307:Risk Factors; D000077157:Sorafenib; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D001557:Benzenesulfonates; D007457:Iodine Radioisotopes; D010671:Phenylurea Compounds; D011725:Pyridines; D015021:Yttrium Radioisotopes; D009536:Niacinamide; D007459:Iodized Oil; D000077157:Sorafenib; D040262:Receptors, Vascular Endothelial Growth Factor